Skip to content Skip to footer
Subscribe Now
Viewpoints_Dr. Barbara Delage_Dr. Nicholas Kassebaum
VIEWPOINTS

Dr. Barbara Delage and Dr. Nicholas Kassebaum Shares Insights on Malnutrition-related Deaths

Shots: Dr. Barbara Delage talked about the key findings from the new study on malnutrition-related deaths. She also spoke about the birth condition, Orofacial cleft Dr. Nicholas Kassebaum spoke about how malnutrition-related deaths could be prevented in children living with a cleft The study was conducted in collaboration with Smile Train and the Institute for…
December 19, 2022

Read more

Viewpoints_Michael Irizarry
VIEWPOINTS

Michael Irizarry, SVP, Clinical Research, Eisai Shares Insights from the Clinical Data of Lecanemab Presented at AAIC

Shots: Michael talked about the new data from its Alzheimer’s pipeline at the Alzheimer’s Association International (AAIC) Michael also highlighted the study design of the P-II & P-III trial evaluating lecanemab The interview gives an understanding of  Eisai’s human health care (hhc) concept which provides innovative products with high unmet medical needs to target diseases…
December 14, 2022

Read more

Viewpoints_Brian Quigley
VIEWPOINTS

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Shots: Brian spoke about why Respira Technologies has been rebranded as Qnovia Brian also talked about how Qnovia is working to advance its first inhalable prescription smoking cessation therapy and its applications The interview summarizes how this rebranding will accelerate Qnovia’s technology and products from others in the biotechnology space  Smriti: Would you please start off…
December 12, 2022

Read more

Viewpoints_Dr. Volker Knappertz
VIEWPOINTS

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Shots: Volker spoke about the granting of marketing authorization by EC to treat adults with active lupus nephritis.The approval was based on the results of the P-III AURORA study  Volker also talked about the collaboration between Aurinia and Otsuka Pharmaceutical for the development and commercialization of LUPKYNIS The interview gives an understanding of how Aurinia…
December 7, 2022

Read more

Viewpoints_Dr. Robert Kowal
VIEWPOINTS

Dr. Robert Kowal, Vice President at Medtronic Shares Insights on a New Clinical Study on Micra AV Leadless Pacing Performance

Shots: Robert spoke about the publication of the new study in the Heart Rhythm Journal about the Micra AV leadless pacemaker and how it is an effective therapy for patients with atrioventricular (AV) block  Robert talked about the study design and the key findings from the study evaluating Medtronic’s Micra AV device  The interview gives an understanding…
December 6, 2022

Read more

Viewpoints_Priya Singhal
VIEWPOINTS

Priya Singhal, Senior Vice President at Biogen, Shares Insights from Litifilimab Systemic Lupus Erythematosus NEJM Publication

Shots: Priya spoke about the study design and key findings from the P-II (LILAC), P-III (TOPAZ-1) & (TOPAZ-2) clinical study evaluating litifilimab She also talked about the P-III trial evaluating Dapirolizumab pegol in collaboration with UCB to treat SLE The interview summarizes how Biogen’s innovative medications are helping patients with Systemic Lupus Erythematosus which has…
November 30, 2022

Read more

Viewpoints_Patrick Mooney
VIEWPOINTS

Patrick Mooney, CEO at SpyGlass Pharma, Shares Insights from the 3-Month Data of its Innovative Drug Delivery Platform for Chronic Eye Conditions

Shots: Patrick spoke about the 3-month data from the First-in-Human glaucoma treatment trial of Spyglass’ innovative  drug delivery platform that helps in lowering intraocular pressure in patients with glaucoma or ocular hypertension Patrick also talked about the study design and key findings from the First-in-Human glaucoma treatment trial The interview gives an understanding of Spyglass’…
November 29, 2022

Read more

Viewpoints_Tim Clackson
VIEWPOINTS

Tim Clackson, President & CEO of Theseus Pharmaceuticals, Shares Insights on its Pan-Variant Inhibitor Therapies to Treat Cancer

Shots: Tim spoke about the development of THE-349, a fourth-generation small molecule for the treatment of EGFR-mutant NSCLC Tim also talked about Thesus’ other small molecule, THE-630 in gastrointestinal stromal tumors (GIST) being evaluated in a P-I/II dose-escalation and expansion study  The interview gives an understanding of how Thesus is developing different treatment options to…
November 28, 2022

Read more

Load more